Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingInterventionalPhase 3

A Randomized Phase III Trial of Carboplatin, Paclitaxel, Pembrolizumab Versus Carboplatin, Paclitaxel, Bevacizumab Versus Carboplatin, Paclitaxel, Pembrolizumab, Bevacizumab in the Treatment of pMMR, TP53 Mutated Advanced or Recurrent Endometrial Cancer

NCT ID: NCT07198074Sponsor: National Cancer Institute (NCI)Last updated: 2026-06-17

Summary

This phase III trial compares the effect of bevacizumab in combination with carboplatin, paclitaxel and pembrolizumab to the usual treatments of carboplatin and paclitaxel with or without pembrolizumab in treating patients with stage III, IVA or IVB mismatch repair protein proficient (pMMR) and TP53 mutated endometrial cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has come back after a period of improvement (recurrent). Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Carboplatin is in a class of medications known as platinum-containing compounds. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Adding bevacizumab to the combination of carboplatin, paclitaxel and pembrolizumab may be more effective than the usual treatment combinations of carboplatin and paclitaxel with or without pembrolizumab in treating patients with advanced or recurrent pMMR and TP53 mutated endometrial cancer.

Detailed description

PRIMARY OBJECTIVE: I. To demonstrate that bevacizumab, an anti-VEGF antibody therapy, (or an anti-VEGF antibody biosimilar) in combination with carboplatin, paclitaxel, and pembrolizumab is superior to carboplatin, paclitaxel, and pembrolizumab (the control arm) or carboplatin, paclitaxel, and bevacizumab in prolonging progression-free survival (PFS) in patients with pMMR, TP53 mutated advanced stage (III or IV) or recurrent endometrial cancer. SECONDARY OBJECTIVES: I. To demonstrate that bevacizumab in combination with carboplatin, paclitaxel, and pembrolizumab is superior to carboplatin, paclitaxel, and pembrolizumab or carboplatin, paclitaxel, and bevacizumab in prolonging overall survival (OS) in patients with pMMR, TP53 mutated advanced stage (III or IV) or recurrent endometrial cancer. II. To examine the impact of the addition of bevacizumab in combination with carboplatin and paclitaxel or with carboplatin, paclitaxel, and pembrolizumab on PFS and OS based on type of p53 immunohistochemistry (IHC) aberrancy (over expression/cytoplasmic expression versus null \[complete absence of staining\]) and mutation type. III. To evaluate toxicity on treatment with bevacizumab when combined with carboplatin, paclitaxel, and/or pembrolizumab as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version (v.)5.0. IV. To explore the anti-tumor activity in each treatment arm as assessed by objective response rate in the subset of patients with measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. OUTLINE: Patients are randomized to 1 of 3 arms. ARM 1 (REFERENCE ARM): Patients receive paclitaxel intravenously (IV) over 3 hours, carboplatin IV and pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 3 weeks for up to 6-10 cycles in the absence of disease progression or unacceptable toxicity. Starting 3 weeks after last combination phase cycle, patients may continue to receive maintenance pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for up to an additional14 cycles. Additionally, patients undergo urine and blood sample collection and computed tomography (CT) or magnetic resonance imaging (MRI) throughout the study. ARM 2 (EXPERIMENTAL TRIPLET ARM): Patients receive paclitaxel IV over 3 hours, carboplatin IV, and bevacizumab IV or anti-VEGF antibody biosimilar on day 1 of each cycle. Cycles repeat every 3 weeks for up to 6-10 cycles in the absence of disease progression or unacceptable toxicity. Starting 3 weeks after last combination phase cycle, patients may continue to receive maintenance bevacizumab IV on day 1 of each cycle. Treatment repeats every 3 weeks for up to an additional 28 doses. Additionally, patients undergo urine and blood sample collection and CT or MRI throughout the study. ARM 3 (EXPERIMENTAL QUADRUPLET ARM): Patients receive paclitaxel IV over 3 hours, carboplatin IV, pembrolizumab IV over 30 minutes, and bevacizumab IV or anti-VEGF antibody biosimilar on day 1 of each cycle. Cycles repeat every 3 weeks for up to 6-10 cycles in the absence of disease progression or unacceptable toxicity. Starting 3 weeks after last combination phase cycle, patients may continue to receive maintenance pembrolizumab IV over 30 minutes every 6 weeks for up to an additional 14 cycles and bevacizumab IV every 3 weeks for up to an additional 28 doses. Additionally, patients undergo urine and blood sample collection and CT or MRI throughout the study. After completion of study treatment, patients are followed every 3 months for 2 years then every 6 months for up to 3 years.

Arms & interventions

  • BiologicalBevacizumab

    Given IV

  • ProcedureBiospecimen Collection

    Undergo urine and blood sample collection

  • DrugCarboplatin

    Given IV

  • ProcedureComputed Tomography

    Undergo CT

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

  • DrugPaclitaxel

    Given IV

  • BiologicalPembrolizumab

    Given IV

Outcome measures

Primary

  • Progression-free survival (PFS)

    Will be defined using Response Evaluation Criteria in Solid Tumors version (v) 1.1. Will be tested using one-sided log-rank tests with α-levels stratified by factors used in the randomization. Patients will be grouped by their randomized treatment assignment for intention-to-treat (ITT) analyses, supported by patients in ITT population. Treatment hazard ratios and their 95% confidence intervals will be estimated using a Cox proportional hazards models specified with a main effect for the randomized treatment assignment and stratified using the stratification factors applied at randomization.

    Time frame: From study entry to time of progression or death, whichever occurs first, or date of last contact if neither progression nor death has occurred, assessed up to 5 years

Secondary

  • Overall survival (OS)

    Time frame: From study entry to time of death from any cause, assessed up to 5 years

  • Prognostic and predictive associations of type of TP53 mutation status with PFS

    Time frame: Up to 5 years

  • Prognostic and predictive associations of type of TP53 mutation status with OS

    Time frame: Up to 5 years

  • Incidence of adverse events (AEs) in treatment with bevacizumab when combined with carboplatin, paclitaxel, and pembrolizumab

    Time frame: Up to 90 days after last dose of study treatment

  • Objective response rate

    Time frame: Within 12 months of initiating therapy

Eligibility criteria

Sex: FemaleAge: 18 Years and olderHealthy volunteers: No
Inclusion Criteria: * Documentation of disease: * Stage III and stage IVA endometrial cancers (with measurable disease), * Stage IVB endometrial cancer (with or without measurable disease), or * Recurrent endometrial cancer (with or without measurable disease) * In patients with measurable disease, lesions will be defined and monitored by RECIST 1.1. Measurable disease (RECIST 1.1) is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded). Each lesion must be ≥ 10 mm when measured by CT or MRI. Lymph nodes must be ≥ 15 mm in short axis when measured by CT or MRI * Histologic confirmation of the original primary tumor is required (submission of pathology report\[s\] is required). Patients with the following histologic types are eligible: endometrioid, serous, dedifferentiated/undifferentiated, clear cell, mixed epithelial, carcinosarcoma, adenocarcinoma not otherwise specified (N.O.S.) * Patients must have: * Tumoral mismatch repair proficient (pMMR) disease as assessed by immunohistochemistry (IHC) AND * P53 IHC with aberrant staining pattern (aberrant p53 expression is consistent with mutant TP53). TP53 mutation by next-generation sequencing will also be accepted * A pathology report demonstrating results of institutional MMR IHC and p53 IHC and/or TP53 by next-generation sequencing * Patients may have received: * NO prior chemotherapy for treatment of endometrial cancer OR * Prior adjuvant chemotherapy (e.g., paclitaxel/carboplatin alone or as a component of concurrent chemotherapy and radiation therapy \[with or without cisplatin\]) provided adjuvant chemotherapy was completed ≥ 12 months prior to registration * Patients may have received prior radiation therapy for treatment of endometrial cancer. Prior radiation therapy may have included pelvic radiation therapy, extended field pelvic/para-aortic radiation therapy, intravaginal brachytherapy, and/or palliative radiation therapy. All radiation therapy must be completed at least 4 weeks prior to registration. For patients with recent radiation, they must have RECIST-evaluable disease outside of the radiation field and have recovered their marrow function * Patients may have received prior hormonal (endocrine) therapy. All hormonal (endocrine) therapy must have been completed at least 1 week prior to registration * NO prior pembrolizumab (or other anti-PD1, anti-PDL1 or anti-CTLA4 therapy) or bevacizumab (or other antiangiogenic therapy) * Interval or cytoreductive surgery, after start of treatment on this trial, and prior to documentation of disease progression, is NOT permitted * Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of disease progression. Patients with brain metastases must have follow up imaging demonstrating no evidence of disease progression and that the disease is stable off of steroids * Age ≥ 18 * Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2 * Not pregnant and not nursing * Absolute neutrophil count (ANC) ≥ 1,500 cells/mm\^3 * Platelets ≥ 100,000 cells/mm\^3 * Hemoglobin ≥ 8 g/dl * Creatinine clearance (CrCl) of ≥ 30 mL/min by the Cockcroft-Gault formula * Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (patients with known Gilbert's disease who have bilirubin level ≤ 3 x institutional ULN may be enrolled) * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x institutional ULN * Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class II or better * No active infection requiring parenteral antibiotics * No current evidence of intra-abdominal abscess, abdominal/pelvic fistula (not diverted), gastrointestinal perforation, gastrointestinal (GI) obstruction, and/or need for drainage nasogastric or gastrostomy tube * No clinically significant bleeding within 28 days prior to registration * No uncontrolled hypertension, defined as systolic ≥ 160 mm Hg or diastolic ≥ 100 mm Hg * No major surgery within 28 days of initiation of bevacizumab * No active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including corticosteroids. This includes, but is not limited to, patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome because of the risk of recurrence or exacerbation of disease * Patients with vitiligo, endocrine deficiencies including type I diabetes mellitus, thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible * Topical or inhaled steroids are allowed * Patients with rheumatoid arthritis and other arthropathies, Sjogren's syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA), and anti-thyroid antibodies should be evaluated with the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible * No history of (non-infectious) pneumonitis that required steroids, or current pneumonitis * No history of stem cell or solid organ transplant * No history of allergic reaction to the study agent(s) or compounds of similar chemical or biologic composition to the study agent(s) (or any of its excipients)

Study locations (218)

University of Alabama at Birmingham Cancer Center

Birmingham, Alabama, 35233

Recruiting
Site Public Contact · Contact
gingerreeves@uabmc.edu
Michael D. Toboni · Principal Investigator

Alaska Women's Cancer Care

Anchorage, Alaska, 99508

Recruiting
Site Public Contact · Contact
907-212-6871AKPAMC.OncologyResearchSupport@providence.org
Dan S. Zuckerman · Principal Investigator

Cancer Center at Saint Joseph's

Phoenix, Arizona, 85004

Recruiting
Site Public Contact · Contact
720-874-1881ResearchInstituteInquiries@CommonSpirit.org
Shahzad Siddique · Principal Investigator

Highlands Oncology Group - Fayetteville

Fayetteville, Arkansas, 72703

Recruiting
Site Public Contact · Contact
479-872-8100research@hogonc.com
Joseph T. Beck · Principal Investigator

University of Arkansas for Medical Sciences

Little Rock, Arkansas, 72205

Recruiting
Site Public Contact · Contact
501-686-8274
Heather R. Williams · Principal Investigator

Highlands Oncology Group - Rogers

Rogers, Arkansas, 72758

Recruiting
Site Public Contact · Contact
479-872-8130research@hogonc.com
Joseph T. Beck · Principal Investigator

Highlands Oncology Group

Springdale, Arkansas, 72762

Recruiting
Site Public Contact · Contact
479-872-8130research@hogonc.com
Joseph T. Beck · Principal Investigator

Mercy Cancer Center - Carmichael

Carmichael, California, 95608

Recruiting
Site Public Contact · Contact
720-874-1881ResearchInstituteInquiries@CommonSpirit.org
Shahzad Siddique · Principal Investigator

Mercy San Juan Medical Center

Carmichael, California, 95608

Recruiting
Site Public Contact · Contact
720-874-1881ResearchInstituteInquiries@commonspirit.org
Shahzad Siddique · Principal Investigator

Mercy Cancer Center - Elk Grove

Elk Grove, California, 95758

Recruiting
Site Public Contact · Contact
720-874-1881ResearchInstituteInquiries@CommonSpirit.org
Shahzad Siddique · Principal Investigator

Los Angeles General Medical Center

Los Angeles, California, 90033

Recruiting
Site Public Contact · Contact
323-865-0451uscnorrisinfo@med.usc.edu
Koji Matsuo · Principal Investigator

USC / Norris Comprehensive Cancer Center

Los Angeles, California, 90033

Recruiting
Site Public Contact · Contact
323-865-0451
Koji Matsuo · Principal Investigator

Stanford Cancer Institute Palo Alto

Palo Alto, California, 94304

Recruiting
Site Public Contact · Contact
650-498-7061ccto-office@stanford.edu
Kristin L. Bixel · Principal Investigator

Eisenhower Medical Center

Rancho Mirage, California, 92270

Recruiting
Site Public Contact · Contact
760-834-3798
Mark Genesen · Principal Investigator

Mercy Cancer Center - Rocklin

Rocklin, California, 95765

Recruiting
Site Public Contact · Contact
720-874-1881ResearchInstituteInquiries@CommonSpirit.org
Shahzad Siddique · Principal Investigator

Mercy Cancer Center - Sacramento

Sacramento, California, 95816

Recruiting
Site Public Contact · Contact
720-874-1881ResearchInstituteInquiries@CommonSpirit.org
Shahzad Siddique · Principal Investigator

University of California Davis Comprehensive Cancer Center

Sacramento, California, 95817

Recruiting
Site Public Contact · Contact
916-734-3089
Nancy T. Nguyen · Principal Investigator

Woodland Memorial Hospital

Woodland, California, 95695

Recruiting
Site Public Contact · Contact
720-874-1881ResearchInstituteInquiries@CommonSpirit.org
Shahzad Siddique · Principal Investigator

Hartford Hospital

Hartford, Connecticut, 06102

Recruiting
Site Public Contact · Contact
860-545-5363
Amy K. Brown · Principal Investigator

Hartford HealthCare - Manchester

Manchester, Connecticut, 06042

Recruiting
Site Public Contact · Contact
860-972-4700
Amy K. Brown · Principal Investigator

The Hospital of Central Connecticut

New Britain, Connecticut, 06050

Recruiting
Site Public Contact · Contact
860-224-5660
Amy K. Brown · Principal Investigator

Beebe South Coastal Health Campus

Millville, Delaware, 19967

Recruiting
Site Public Contact · Contact
302-291-6730research@beebehealthcare.org
Gregory A. Masters · Principal Investigator

Helen F Graham Cancer Center

Newark, Delaware, 19713

Recruiting
Site Public Contact · Contact
302-623-4450lbarone@christianacare.org
Gregory A. Masters · Principal Investigator

Medical Oncology Hematology Consultants PA

Newark, Delaware, 19713

Recruiting
Site Public Contact · Contact
302-623-4450lbarone@christianacare.org
Gregory A. Masters · Principal Investigator

Beebe Health Campus

Rehoboth Beach, Delaware, 19971

Recruiting
Site Public Contact · Contact
302-291-6730research@beebehealthcare.org
Gregory A. Masters · Principal Investigator

Emory University Hospital Midtown

Atlanta, Georgia, 30308

Recruiting
Site Public Contact · Contact
888-946-7447
Kristen Starbuck · Principal Investigator

Emory University Hospital/Winship Cancer Institute

Atlanta, Georgia, 30322

Recruiting
Site Public Contact · Contact
404-778-1868
Kristen Starbuck · Principal Investigator

Augusta University Medical Center

Augusta, Georgia, 30912

Suspended

Emory Decatur Hospital

Decatur, Georgia, 30033

Recruiting
Site Public Contact · Contact
440-778-1868clinicaltrialsoncology@dekalbmedical.org
Kristen Starbuck · Principal Investigator

Kootenai Health - Coeur d'Alene

Coeur d'Alene, Idaho, 83814

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Kootenai Clinic Cancer Services - Post Falls

Post Falls, Idaho, 83854

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Kootenai Clinic Cancer Services - Sandpoint

Sandpoint, Idaho, 83864

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Northwestern University

Chicago, Illinois, 60611

Recruiting
Site Public Contact · Contact
312-695-1301cancer@northwestern.edu
Emma Barber · Principal Investigator

Rush MD Anderson Cancer Center

Chicago, Illinois, 60612

Recruiting
Site Public Contact · Contact
312-226-2371Cancer_Studies@rush.edu
Alexander C. Cohen · Principal Investigator

Cancer Care Specialists of Illinois - Decatur

Decatur, Illinois, 62526

Recruiting
Site Public Contact · Contact
217-876-4762morganthaler.jodi@mhsil.com
Bryan A. Faller · Principal Investigator

Decatur Memorial Hospital

Decatur, Illinois, 62526

Recruiting
Site Public Contact · Contact
217-876-4762morganthaler.jodi@mhsil.com
Bryan A. Faller · Principal Investigator

Northwestern Medicine Cancer Center Kishwaukee

DeKalb, Illinois, 60115

Recruiting
Site Public Contact · Contact
630-352-5360Donald.Smith3@nm.org
Emma Barber · Principal Investigator

Northwestern Medicine Cancer Center Delnor

Geneva, Illinois, 60134

Recruiting
Site Public Contact · Contact
630-352-5360Donald.Smith3@nm.org
Emma Barber · Principal Investigator

Cancer Care Center of O'Fallon

O'Fallon, Illinois, 62269

Recruiting
Site Public Contact · Contact
217-876-4762morganthaler.jodi@mhsil.com
Bryan A. Faller · Principal Investigator

HSHS Saint Elizabeth's Hospital

O'Fallon, Illinois, 62269

Recruiting
Site Public Contact · Contact
217-876-4762morganthaler.jodi@mhsil.com
Bryan A. Faller · Principal Investigator

Northwestern Medicine Oak Brook

Oak Brook, Illinois, 60523

Recruiting
Site Public Contact · Contact
nctnprogram_rhlccc@northwestern.edu
Emma Barber · Principal Investigator

Rush MD Anderson Cancer Center at Rush Oak Park

Oak Park, Illinois, 60304

Recruiting
Site Public Contact · Contact
312-226-2371Cancer_Studies@rush.edu
Alexander C. Cohen · Principal Investigator

Northwestern Medicine Orland Park

Orland Park, Illinois, 60462

Recruiting
Site Public Contact · Contact
nctnprogram_rhlccc@northwestern.edu
Emma Barber · Principal Investigator

OSF Saint Francis Medical Center

Peoria, Illinois, 61637

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Southern Illinois University School of Medicine

Springfield, Illinois, 62702

Recruiting
Site Public Contact · Contact
217-545-7929
Bryan A. Faller · Principal Investigator

Springfield Clinic

Springfield, Illinois, 62702

Recruiting
Site Public Contact · Contact
800-444-7541
Bryan A. Faller · Principal Investigator

Springfield Memorial Hospital

Springfield, Illinois, 62781

Recruiting
Site Public Contact · Contact
217-528-7541pallante.beth@mhsil.com
Bryan A. Faller · Principal Investigator

Northwestern Medicine Cancer Center Warrenville

Warrenville, Illinois, 60555

Recruiting
Site Public Contact · Contact
630-352-5360Donald.Smith3@nm.org
Emma Barber · Principal Investigator

Goshen Center for Cancer Care

Goshen, Indiana, 46526

Recruiting
Site Public Contact · Contact
574-364-2973cccois@goshenhealth.com
Pamela J. Stone · Principal Investigator

Memorial Hospital of South Bend

South Bend, Indiana, 46601

Recruiting
Site Public Contact · Contact
800-284-7370
LaToya J. Perry · Principal Investigator

UI Health Care Mission Cancer and Blood - Ankeny Clinic

Ankeny, Iowa, 50023

Recruiting
Site Public Contact · Contact
515-241-3305
Seema Harichand-Herdt · Principal Investigator

Saint Anthony Regional Hospital

Carroll, Iowa, 51401

Recruiting
Site Public Contact · Contact
515-689-7658sbenson@iora.org
Seema Harichand-Herdt · Principal Investigator

Mercy Hospital

Cedar Rapids, Iowa, 52403

Recruiting
Site Public Contact · Contact
319-365-4673
Deborah W. Wilbur · Principal Investigator

Oncology Associates at Mercy Medical Center

Cedar Rapids, Iowa, 52403

Recruiting
Site Public Contact · Contact
319-363-2690
Deborah W. Wilbur · Principal Investigator

UI Health Care Mission Cancer and Blood - West Des Moines Clinic

Clive, Iowa, 50325

Recruiting
Site Public Contact · Contact
515-241-3305
Seema Harichand-Herdt · Principal Investigator

Iowa Methodist Medical Center

Des Moines, Iowa, 50309

Recruiting
Site Public Contact · Contact
515-241-6727
Seema Harichand-Herdt · Principal Investigator

UI Health Care Mission Cancer and Blood - Des Moines Clinic

Des Moines, Iowa, 50309

Recruiting
Site Public Contact · Contact
515-241-3305
Seema Harichand-Herdt · Principal Investigator

Broadlawns Medical Center

Des Moines, Iowa, 50314

Recruiting
Site Public Contact · Contact
515-282-2200
Seema Harichand-Herdt · Principal Investigator

Mercy Medical Center - Des Moines

Des Moines, Iowa, 50314

Recruiting
Site Public Contact · Contact
515-241-3305
Richard L. Deming · Principal Investigator

UI Health Care Mission Cancer and Blood - Laurel Clinic

Des Moines, Iowa, 50314

Recruiting
Site Public Contact · Contact
515-241-3305
Seema Harichand-Herdt · Principal Investigator

UI Healthcare Mission Cancer and Blood - Fort Dodge

Fort Dodge, Iowa, 50501

Recruiting
Site Public Contact · Contact
515-282-2921trials@missioncancer.com
Seema Harichand-Herdt · Principal Investigator

University of Iowa/Holden Comprehensive Cancer Center

Iowa City, Iowa, 52242

Recruiting
Site Public Contact · Contact
800-237-1225
David P. Bender · Principal Investigator

UI Health Care Mission Cancer and Blood - Waukee Clinic

Waukee, Iowa, 50263

Recruiting
Site Public Contact · Contact
515-241-3305
Seema Harichand-Herdt · Principal Investigator

University of Kentucky/Markey Cancer Center

Lexington, Kentucky, 40536

Recruiting
Site Public Contact · Contact
859-257-3379
Rachel W. Miller · Principal Investigator

West Jefferson Medical Center

Marrero, Louisiana, 70072

Recruiting
Site Public Contact · Contact
504-210-3539emede1@lsuhsc.edu
Tara Castellano · Principal Investigator

East Jefferson General Hospital

Metairie, Louisiana, 70006

Recruiting
Site Public Contact · Contact
504-210-3539emede1@lsuhsc.edu
Tara Castellano · Principal Investigator

LSU Healthcare Network / Metairie Multi-Specialty Clinic

Metairie, Louisiana, 70006

Recruiting
Site Public Contact · Contact
504-210-3539emede1@lsuhsc.edu
Tara Castellano · Principal Investigator

University Medical Center New Orleans

New Orleans, Louisiana, 70112

Recruiting
Site Public Contact · Contact
504-210-3539emede1@lsuhsc.edu
Tara Castellano · Principal Investigator

MaineHealth Maine Medical Center- Scarborough

Scarborough, Maine, 04074

Recruiting
Site Public Contact · Contact
207-396-8670clinicalresearch@mainehealth.org
Leslie S. Bradford · Principal Investigator

Johns Hopkins University/Sidney Kimmel Cancer Center

Baltimore, Maryland, 21287

Recruiting
Site Public Contact · Contact
410-955-8804jhcccro@jhmi.edu
Amanda N. Fader · Principal Investigator

Dana-Farber Cancer Institute

Boston, Massachusetts, 02215

Recruiting
Site Public Contact · Contact
877-442-3324
Susana M. Campos · Principal Investigator

University of Michigan Rogel Cancer Center

Ann Arbor, Michigan, 48109

Recruiting
Site Public Contact · Contact
800-865-1125CancerAnswerLine@med.umich.edu
Zhen Ni Zhou · Principal Investigator

Bronson Battle Creek

Battle Creek, Michigan, 49017

Recruiting
Site Public Contact · Contact
616-391-1230crcwm-regulatory@crcwm.org
Kathleen Y. Butler · Principal Investigator

Trinity Health IHA Medical Group Hematology Oncology - Brighton

Brighton, Michigan, 48114

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
J. R. Liu · Principal Investigator

University of Michigan - Brighton Center for Specialty Care

Brighton, Michigan, 48116

Recruiting
Site Public Contact · Contact
800-865-1125
Zhen Ni Zhou · Principal Investigator

Trinity Health IHA Medical Group Hematology Oncology - Canton

Canton, Michigan, 48188

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
J. R. Liu · Principal Investigator

Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital

Chelsea, Michigan, 48118

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
J. R. Liu · Principal Investigator

OSF Saint Francis Hospital and Medical Group

Escanaba, Michigan, 49829

Recruiting
Site Public Contact · Contact
920-433-8889WI_research_admin@hshs.org
Matthew L. Ryan · Principal Investigator

Genesys Hurley Cancer Institute

Flint, Michigan, 48503

Recruiting
Site Public Contact · Contact
810-762-8038wstrong@ghci.org
J. R. Liu · Principal Investigator

Hurley Medical Center

Flint, Michigan, 48503

Recruiting
Site Public Contact · Contact
810-762-8038wstrong@ghci.org
J. R. Liu · Principal Investigator

Corewell Health Grand Rapids Hospitals - Butterworth Hospital

Grand Rapids, Michigan, 49503

Recruiting
Site Public Contact · Contact
616-391-1230crcwm-regulatory@crcwm.org
Kathleen Y. Butler · Principal Investigator

Trinity Health Grand Rapids Hospital

Grand Rapids, Michigan, 49503

Recruiting
Site Public Contact · Contact
616-391-1230crcwm-regulatory@crcwm.org
Kathleen Y. Butler · Principal Investigator

Bronson Methodist Hospital

Kalamazoo, Michigan, 49007

Recruiting
Site Public Contact · Contact
616-391-1230crcwm-regulatory@crcwm.org
Kathleen Y. Butler · Principal Investigator

West Michigan Cancer Center

Kalamazoo, Michigan, 49007

Recruiting
Site Public Contact · Contact
616-391-1230crcwm-regulatory@crcwm.org
Kathleen Y. Butler · Principal Investigator

Beacon Kalamazoo Cancer Center

Kalamazoo, Michigan, 49009

Recruiting
Site Public Contact · Contact
574-647-7370
Kathleen Y. Butler · Principal Investigator

Trinity Health Saint Mary Mercy Livonia Hospital

Livonia, Michigan, 48154

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
J. R. Liu · Principal Investigator

Trinity Health Muskegon Hospital

Muskegon, Michigan, 49444

Recruiting
Site Public Contact · Contact
616-391-1230crcwm-regulatory@crcwm.org
Kathleen Y. Butler · Principal Investigator

Corewell Health Lakeland Hospitals - Niles Hospital

Niles, Michigan, 49120

Recruiting
Site Public Contact · Contact
616-391-1230
Kathleen Y. Butler · Principal Investigator

Cancer and Hematology Centers of Western Michigan - Norton Shores

Norton Shores, Michigan, 49444

Recruiting
Site Public Contact · Contact
616-391-1230connie.szczepanek@crcwm.org
Kathleen Y. Butler · Principal Investigator

Trinity Health Saint Joseph Mercy Oakland Hospital

Pontiac, Michigan, 48341

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
J. R. Liu · Principal Investigator

Corewell Health Reed City Hospital

Reed City, Michigan, 49677

Recruiting
Site Public Contact · Contact
616-391-1230crcwm-regulatory@crcwm.org
Kathleen Y. Butler · Principal Investigator

Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center

Saint Joseph, Michigan, 49085

Recruiting
Site Public Contact · Contact
616-391-1230crcwm-regulatory@crcwm.org
Kathleen Y. Butler · Principal Investigator

Corewell Health Lakeland Hospitals - Saint Joseph Hospital

Saint Joseph, Michigan, 49085

Recruiting
Site Public Contact · Contact
616-391-1230crcwm-regulatory@crcwm.org
Kathleen Y. Butler · Principal Investigator

Munson Medical Center

Traverse City, Michigan, 49684

Recruiting
Site Public Contact · Contact
616-391-1230crcwm-regulatory@crcwm.org
Kathleen Y. Butler · Principal Investigator

University of Michigan Health - West

Wyoming, Michigan, 49519

Recruiting
Site Public Contact · Contact
616-391-1230crcwm-regulatory@crcwm.org
Kathleen Y. Butler · Principal Investigator

Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus

Ypsilanti, Michigan, 48197

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
J. R. Liu · Principal Investigator

Essentia Health Saint Joseph's Medical Center

Brainerd, Minnesota, 56401

Recruiting
Site Public Contact · Contact
218-786-3308CancerTrials@EssentiaHealth.org
Bret E. Friday · Principal Investigator

Mercy Hospital

Coon Rapids, Minnesota, 55433

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
Yan Ji · Principal Investigator

Essentia Health - Deer River Clinic

Deer River, Minnesota, 56636

Recruiting
Site Public Contact · Contact
218-786-3308CancerTrials@EssentiaHealth.org
Bret E. Friday · Principal Investigator

Essentia Health Cancer Center

Duluth, Minnesota, 55805

Recruiting
Site Public Contact · Contact
218-786-3308CancerTrials@EssentiaHealth.org
Bret E. Friday · Principal Investigator

Fairview Southdale Hospital

Edina, Minnesota, 55435

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
Yan Ji · Principal Investigator

Essentia Health Hibbing Clinic

Hibbing, Minnesota, 55746

Recruiting
Site Public Contact · Contact
218-786-3308
Bret E. Friday · Principal Investigator

Abbott-Northwestern Hospital

Minneapolis, Minnesota, 55407

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
Yan Ji · Principal Investigator

Park Nicollet Clinic - Saint Louis Park

Saint Louis Park, Minnesota, 55416

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
Yan Ji · Principal Investigator

Regions Hospital

Saint Paul, Minnesota, 55101

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
Yan Ji · Principal Investigator

United Hospital

Saint Paul, Minnesota, 55102

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
Yan Ji · Principal Investigator

Essentia Health Sandstone

Sandstone, Minnesota, 55072

Recruiting
Site Public Contact · Contact
218-786-3308CancerTrials@EssentiaHealth.org
Bret E. Friday · Principal Investigator

Essentia Health Virginia Clinic

Virginia, Minnesota, 55792

Recruiting
Site Public Contact · Contact
218-786-3308CancerTrials@EssentiaHealth.org
Bret E. Friday · Principal Investigator

Minnesota Oncology Hematology PA-Woodbury

Woodbury, Minnesota, 55125

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
Yan Ji · Principal Investigator

Mercy Hospital Springfield

Springfield, Missouri, 65804

Recruiting
Site Public Contact · Contact
417-269-4520
Jay W. Carlson · Principal Investigator

CoxHealth South Hospital

Springfield, Missouri, 65807

Recruiting
Site Public Contact · Contact
417-269-4520
Jay W. Carlson · Principal Investigator

Community Hospital of Anaconda

Anaconda, Montana, 59711

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Billings Clinic Cancer Center

Billings, Montana, 59101

Recruiting
Site Public Contact · Contact
800-996-2663research@billingsclinic.org
John M. Schallenkamp · Principal Investigator

Bozeman Health Deaconess Hospital

Bozeman, Montana, 59715

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Benefis Sletten Cancer Institute

Great Falls, Montana, 59405

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Logan Health Medical Center

Kalispell, Montana, 59901

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Community Medical Center

Missoula, Montana, 59804

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Nebraska Medicine-Bellevue

Bellevue, Nebraska, 68123

Recruiting
Site Public Contact · Contact
402-559-6941unmcrsa@unmc.edu
Lindsey A. McAlarnen · Principal Investigator

Fred and Pamela Buffett Cancer Center - Kearney

Kearney, Nebraska, 68845

Recruiting
Site Public Contact · Contact
402-559-6941unmcrsa@unmc.edu
Lindsey A. McAlarnen · Principal Investigator

Nebraska Methodist Hospital

Omaha, Nebraska, 68114

Recruiting
Site Public Contact · Contact
402-354-5144
Brent J. Tierney · Principal Investigator

Nebraska Medicine-Village Pointe

Omaha, Nebraska, 68118

Recruiting
Site Public Contact · Contact
402-559-5600
Lindsey A. McAlarnen · Principal Investigator

University of Nebraska Medical Center

Omaha, Nebraska, 68198

Recruiting
Site Public Contact · Contact
402-559-6941unmcrsa@unmc.edu
Lindsey A. McAlarnen · Principal Investigator

Women's Cancer Center of Nevada

Las Vegas, Nevada, 89106

Recruiting
Site Public Contact · Contact
702-851-4672
Nicola M. Spirtos · Principal Investigator

Memorial Sloan Kettering Basking Ridge

Basking Ridge, New Jersey, 07920

Recruiting
Site Public Contact · Contact
212-639-7592
Carol Aghajanian · Principal Investigator

Memorial Sloan Kettering Monmouth

Middletown, New Jersey, 07748

Recruiting
Site Public Contact · Contact
212-639-7592
Carol Aghajanian · Principal Investigator

Memorial Sloan Kettering Bergen

Montvale, New Jersey, 07645

Recruiting
Site Public Contact · Contact
212-639-7592
Carol Aghajanian · Principal Investigator

Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08903

Recruiting
Site Public Contact · Contact
732-235-7356
Eugenia Girda · Principal Investigator

Rutgers New Jersey Medical School

Newark, New Jersey, 07101

Recruiting
Site Public Contact · Contact
732-235-7356
Eugenia Girda · Principal Investigator

The Valley Hospital - Luckow Pavilion

Paramus, New Jersey, 07652

Recruiting
Site Public Contact · Contact
201-634-5792clinicaltrialsresearch@valleyhealth.com
Eleonora Teplinsky · Principal Investigator

Valley Health System Ridgewood Campus

Ridgewood, New Jersey, 07450

Recruiting
Site Public Contact · Contact
201-634-5792clinicaltrialsresearch@valleyhealth.com
Eleonora Teplinsky · Principal Investigator

Sidney Kimmel Cancer Center Washington Township

Sewell, New Jersey, 08080

Recruiting
Site Public Contact · Contact
215-600-9151ONCTrialNow@jefferson.edu
Jessa Suhner · Principal Investigator

University of New Mexico Cancer Center

Albuquerque, New Mexico, 87106

Recruiting
Site Public Contact · Contact
505-925-0348HSC-ClinicalTrialInfo@salud.unm.edu
Amaranta D. Craig · Principal Investigator

Northwell Health Imbert Cancer Center

Bay Shore, New York, 11706

Recruiting
Site Public Contact · Contact
516-734-8896
Veena S. John · Principal Investigator

Memorial Sloan Kettering Commack

Commack, New York, 11725

Recruiting
Site Public Contact · Contact
212-639-7592
Carol Aghajanian · Principal Investigator

Northwell Health Physician Partners at Flushing

Flushing, New York, 11354

Recruiting
Site Public Contact · Contact
718-559-3600nhppflushing@northwell.edu
Veena S. John · Principal Investigator

Northwell Health Cancer Institute at Huntington

Greenlawn, New York, 11740

Recruiting
Site Public Contact · Contact
516-734-8896
Veena S. John · Principal Investigator

Memorial Sloan Kettering Westchester

Harrison, New York, 10604

Recruiting
Site Public Contact · Contact
212-639-7592
Carol Aghajanian · Principal Investigator

Northwell Health/Center for Advanced Medicine

Lake Success, New York, 11042

Recruiting
Site Public Contact · Contact
516-734-8896
Veena S. John · Principal Investigator

Manhattan Eye Ear and Throat Hospital

New York, New York, 10065

Recruiting
Site Public Contact · Contact
212-434-4460
Veena S. John · Principal Investigator

Memorial Sloan Kettering Cancer Center

New York, New York, 10065

Recruiting
Site Public Contact · Contact
212-639-7592
Carol Aghajanian · Principal Investigator

Lenox Hill Hospital

New York, New York, 10075

Recruiting
Site Public Contact · Contact
516-734-8896
Veena S. John · Principal Investigator

Queens Cancer Center

Rego Park, New York, 11374

Recruiting
Site Public Contact · Contact
718-312-3446
Veena S. John · Principal Investigator

University of Rochester

Rochester, New York, 14642

Recruiting
Site Public Contact · Contact
585-275-5830
Rachael Turner · Principal Investigator

Phelps Memorial Hospital Center

Sleepy Hollow, New York, 10591

Recruiting
Site Public Contact · Contact
914-366-1600
Veena S. John · Principal Investigator

Staten Island University Hospital

Staten Island, New York, 10305

Recruiting
Site Public Contact · Contact
718-226-8888
Veena S. John · Principal Investigator

Stony Brook University Medical Center

Stony Brook, New York, 11794

Recruiting
Site Public Contact · Contact
800-862-2215
Susan M. Lang · Principal Investigator

Montefiore Medical Center-Einstein Campus

The Bronx, New York, 10461

Recruiting
Site Public Contact · Contact
718-379-6866eskwak@montefiore.org
Nicole S. Nevadunsky · Principal Investigator

Montefiore Medical Center-Weiler Hospital

The Bronx, New York, 10461

Recruiting
Site Public Contact · Contact
718-379-6866eskwak@montefiore.org
Nicole S. Nevadunsky · Principal Investigator

Montefiore Medical Center - Moses Campus

The Bronx, New York, 10467

Recruiting
Site Public Contact · Contact
718-379-6866eskwak@montefiore.org
Nicole S. Nevadunsky · Principal Investigator

Memorial Sloan Kettering Nassau

Uniondale, New York, 11553

Recruiting
Site Public Contact · Contact
212-639-7592
Carol Aghajanian · Principal Investigator

UNC Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina, 27599

Recruiting
Site Public Contact · Contact
877-668-0683cancerclinicaltrials@med.unc.edu
Olivia D. Lara · Principal Investigator

Southeastern Medical Oncology Center-Clinton

Clinton, North Carolina, 28328

Recruiting
Site Public Contact · Contact
919-587-9084jfields@cancersmoc.com
Samer S. Kasbari · Principal Investigator

Duke University Medical Center

Durham, North Carolina, 27710

Recruiting
Site Public Contact · Contact
888-275-3853
Angeles A. Secord · Principal Investigator

Southeastern Medical Oncology Center-Goldsboro

Goldsboro, North Carolina, 27534

Recruiting
Site Public Contact · Contact
919-587-9084jfields@cancersmoc.com
Samer S. Kasbari · Principal Investigator

Southeastern Medical Oncology Center-Jacksonville

Jacksonville, North Carolina, 28546

Recruiting
Site Public Contact · Contact
910-587-9084jfields@cancersmoc.com
Samer S. Kasbari · Principal Investigator

Duke Women's Cancer Care Raleigh

Raleigh, North Carolina, 27607

Recruiting
Site Public Contact · Contact
919-785-4878
Angeles A. Secord · Principal Investigator

Essentia Health Cancer Center-South University Clinic

Fargo, North Dakota, 58103

Recruiting
Site Public Contact · Contact
218-786-3308CancerTrials@EssentiaHealth.org
Bret E. Friday · Principal Investigator

OhioHealth O'Bleness Hospital

Athens, Ohio, 45701

Recruiting
Site Public Contact · Contact
614-788-3860Jennifer.Sexton@ohiohealth.com
Aine E. Clements · Principal Investigator

UHHS-Chagrin Highlands Medical Center

Beachwood, Ohio, 44122

Recruiting
Site Public Contact · Contact
800-641-2422CTUReferral@UHhospitals.org
Amy Armstrong · Principal Investigator

Geauga Hospital

Chardon, Ohio, 44024

Recruiting
Site Public Contact · Contact
800-641-2422CTUReferral@UHhospitals.org
Amy Armstrong · Principal Investigator

Case Western Reserve University

Cleveland, Ohio, 44106

Recruiting
Site Public Contact · Contact
800-641-2422CTUReferral@UHhospitals.org
Amy Armstrong · Principal Investigator

Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210

Recruiting
Site Public Contact · Contact
800-293-5066Jamesline@osumc.edu
Floor Backes · Principal Investigator

Columbus Oncology and Hematology Associates Inc

Columbus, Ohio, 43214

Recruiting
Site Public Contact · Contact
614-788-3860Jennifer.Sexton@ohiohealth.com
Aine E. Clements · Principal Investigator

Riverside Methodist Hospital

Columbus, Ohio, 43214

Recruiting
Site Public Contact · Contact
614-788-3860Jennifer.Sexton@ohiohealth.com
Aine E. Clements · Principal Investigator

Grant Medical Center

Columbus, Ohio, 43215

Recruiting
Site Public Contact · Contact
614-788-3860Jennifer.Sexton@ohiohealth.com
Aine E. Clements · Principal Investigator

Doctors Hospital

Columbus, Ohio, 43228

Recruiting
Site Public Contact · Contact
614-788-3860Jennifer.Sexton@ohiohealth.com
Aine E. Clements · Principal Investigator

Delaware Health Center-Grady Cancer Center

Delaware, Ohio, 43015

Recruiting
Site Public Contact · Contact
614-788-3860Jennifer.Sexton@ohiohealth.com
Aine E. Clements · Principal Investigator

Grady Memorial Hospital

Delaware, Ohio, 43015

Recruiting
Site Public Contact · Contact
614-788-3860Jennifer.Sexton@ohiohealth.com
Aine E. Clements · Principal Investigator

Columbus Oncology and Hematology Associates

Dublin, Ohio, 43016

Recruiting
Site Public Contact · Contact
614-788-3860Jennifer.Sexton@ohiohealth.com
Aine E. Clements · Principal Investigator

Dublin Methodist Hospital

Dublin, Ohio, 43016

Recruiting
Site Public Contact · Contact
614-788-3860Jennifer.Sexton@ohiohealth.com
Aine E. Clements · Principal Investigator

OhioHealth Mansfield Hospital

Mansfield, Ohio, 44903

Recruiting
Site Public Contact · Contact
614-788-3860Jennifer.Sexton@ohiohealth.com
Aine E. Clements · Principal Investigator

OhioHealth Marion General Hospital

Marion, Ohio, 43302

Recruiting
Site Public Contact · Contact
614-788-3860Jennifer.Sexton@ohiohealth.com
Aine E. Clements · Principal Investigator

UH Seidman Cancer Center at Lake Health Mentor Campus

Mentor, Ohio, 44060

Recruiting
Site Public Contact · Contact
800-641-2422CTUReferral@UHhospitals.org
Amy Armstrong · Principal Investigator

University Hospitals Parma Medical Center

Parma, Ohio, 44129

Recruiting
Site Public Contact · Contact
800-641-2422CTUReferral@UHhospitals.org
Amy Armstrong · Principal Investigator

OhioHealth Pickerington Methodist Hospital

Pickerington, Ohio, 43147

Recruiting
Site Public Contact · Contact
614-788-3860Jennifer.Sexton@ohiohealth.com
Aine E. Clements · Principal Investigator

ProMedica Flower Hospital

Sylvania, Ohio, 43560

Recruiting
Site Public Contact · Contact
419-824-1842PCIOncResearch@promedica.org
Anjalika Gandhi · Principal Investigator

OhioHealth Westerville Medical Campus/Westerville Cancer Center

Westerville, Ohio, 43082

Recruiting
Site Public Contact · Contact
610-788-3860Jennifer.Sexton@ohiohealth.com
Aine E. Clements · Principal Investigator

UH Seidman Cancer Center at Saint John Medical Center

Westlake, Ohio, 44145

Recruiting
Site Public Contact · Contact
800-641-2422CTUReferral@UHhospitals.org
Amy Armstrong · Principal Investigator

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104

Recruiting
Site Public Contact · Contact
405-271-8777ou-clinical-trials@ouhsc.edu
Grace Duininck · Principal Investigator

Legacy Good Samaritan Hospital and Medical Center

Portland, Oregon, 97210

Recruiting
Site Public Contact · Contact
800-220-4937cancer@lhs.org
Julia Fehniger · Principal Investigator

Providence Portland Medical Center

Portland, Oregon, 97213

Recruiting
Site Public Contact · Contact
503-215-2614CanRsrchStudies@providence.org
Dan S. Zuckerman · Principal Investigator

Providence Saint Vincent Medical Center

Portland, Oregon, 97225

Recruiting
Site Public Contact · Contact
503-215-2614CanRsrchStudies@providence.org
Dan S. Zuckerman · Principal Investigator

Legacy Meridian Park Hospital

Tualatin, Oregon, 97062

Recruiting
Site Public Contact · Contact
503-413-1742
Julia Fehniger · Principal Investigator

UPMC Hillman Cancer Center Erie

Erie, Pennsylvania, 16505

Recruiting
Site Public Contact · Contact
412-864-7716ClinicalResearchServices@upmc.edu
Sarah E. Taylor · Principal Investigator

UPMC Cancer Centers - Arnold Palmer Pavilion

Greensburg, Pennsylvania, 15601

Recruiting
Site Public Contact · Contact
724-838-1900
Sarah E. Taylor · Principal Investigator

UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion

Mechanicsburg, Pennsylvania, 17050

Recruiting
Site Public Contact · Contact
412-389-5208haneydl@upmc.edu
Sarah E. Taylor · Principal Investigator

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, 19107

Recruiting
Site Public Contact · Contact
215-600-9151ONCTrialNow@jefferson.edu
Jessa Suhner · Principal Investigator

Jefferson Torresdale Hospital

Philadelphia, Pennsylvania, 19114

Recruiting
Site Public Contact · Contact
215-600-9151ONCTrialNow@jefferson.edu
Jessa Suhner · Principal Investigator

UPMC-Magee Womens Hospital

Pittsburgh, Pennsylvania, 15213

Recruiting
Site Public Contact · Contact
412-647-2811
Sarah E. Taylor · Principal Investigator

UPMC-Passavant Hospital

Pittsburgh, Pennsylvania, 15237

Recruiting
Site Public Contact · Contact
412-367-6454
Sarah E. Taylor · Principal Investigator

UPMC Cancer Center-Washington

Washington, Pennsylvania, 15301

Recruiting
Site Public Contact · Contact
412-339-5294Roster@nrgoncology.org
Sarah E. Taylor · Principal Investigator

Asplundh Cancer Pavilion

Willow Grove, Pennsylvania, 19090

Recruiting
Site Public Contact · Contact
215-600-9151ONCTrialNow@jefferson.edu
Jessa Suhner · Principal Investigator

Women and Infants Hospital

Providence, Rhode Island, 02905

Recruiting
Site Public Contact · Contact
401-274-1122
Paul A. DiSilvestro · Principal Investigator

Vanderbilt University/Ingram Cancer Center

Nashville, Tennessee, 37232

Recruiting
Site Public Contact · Contact
800-811-8480
Alaina J. Brown · Principal Investigator

University of Utah Sugarhouse Health Center

Salt Lake City, Utah, 84106

Recruiting
Site Public Contact · Contact
888-424-2100cancerinfo@hci.utah.edu
Talicia Savage · Principal Investigator

Huntsman Cancer Institute/University of Utah

Salt Lake City, Utah, 84112

Recruiting
Site Public Contact · Contact
888-424-2100cancerinfo@hci.utah.edu
Talicia Savage · Principal Investigator

South Jordan Health Center

South Jordan, Utah, 84009

Recruiting
Site Public Contact · Contact
888-424-2100cancerinfo@hci.utah.edu
Talicia Savage · Principal Investigator

University of Virginia Cancer Center

Charlottesville, Virginia, 22908

Recruiting
Site Public Contact · Contact
434-243-6303uvacancertrials@hscmail.mcc.virginia.edu
Linda R. Duska · Principal Investigator

VCU Massey Comprehensive Cancer Center

Richmond, Virginia, 23298

Recruiting
Site Public Contact · Contact
804-628-6430CTOclinops@vcu.edu
Jaclyn Wall · Principal Investigator

Swedish Cancer Institute-Edmonds

Edmonds, Washington, 98026

Recruiting
Site Public Contact · Contact
206-215-2343PCRC-NCORP@Swedish.org
Dan S. Zuckerman · Principal Investigator

Swedish Cancer Institute-Issaquah

Issaquah, Washington, 98029

Recruiting
Site Public Contact · Contact
206-215-2343PCRC-NCORP@Swedish.org
Dan S. Zuckerman · Principal Investigator

Swedish Medical Center-First Hill

Seattle, Washington, 98122

Recruiting
Site Public Contact · Contact
206-215-2343PCRC-NCORP@Swedish.org
Dan S. Zuckerman · Principal Investigator

Legacy Salmon Creek Hospital

Vancouver, Washington, 98686

Recruiting
Site Public Contact · Contact
503-413-2150
Julia Fehniger · Principal Investigator

United Hospital Center

Bridgeport, West Virginia, 26330

Recruiting
Site Public Contact · Contact
304-293-7374cancertrialsinfo@hsc.wvu.edu
Krista S. Pfaendler · Principal Investigator

West Virginia University Charleston Division

Charleston, West Virginia, 25304

Recruiting
Site Public Contact · Contact
304-388-9944
Stephen H. Bush · Principal Investigator

WVUH-Berkely Medical Center

Martinsburg, West Virginia, 25401

Recruiting
Site Public Contact · Contact
304-293-7374cancertrialsinfo@hsc.wvu.edu
Krista S. Pfaendler · Principal Investigator

West Virginia University Healthcare

Morgantown, West Virginia, 26506

Recruiting
Site Public Contact · Contact
304-293-7374cancertrialsinfo@hsc.wvu.edu
Krista S. Pfaendler · Principal Investigator

Camden Clark Medical Center

Parkersburg, West Virginia, 26101

Recruiting
Site Public Contact · Contact
304-293-7374cancertrialsinfo@hsc.wvu.edu
Krista S. Pfaendler · Principal Investigator

Duluth Clinic Ashland

Ashland, Wisconsin, 54806

Recruiting
Site Public Contact · Contact
218-786-3308CancerTrials@EssentiaHealth.org
Bret E. Friday · Principal Investigator

Saint Vincent Hospital Cancer Center Green Bay

Green Bay, Wisconsin, 54301

Recruiting
Site Public Contact · Contact
920-433-8889WI_research_admin@hshs.org
Matthew L. Ryan · Principal Investigator

Saint Vincent Hospital Cancer Center at Saint Mary's

Green Bay, Wisconsin, 54303

Recruiting
Site Public Contact · Contact
920-433-8889wi_research_admin@hshs.org
Matthew L. Ryan · Principal Investigator

Gundersen Lutheran Medical Center

La Crosse, Wisconsin, 54601

Recruiting
Site Public Contact · Contact
608-775-2385cancerctr@gundersenhealth.org
Kurt Oettel · Principal Investigator

Saint Vincent Hospital Cancer Center at Oconto Falls

Oconto Falls, Wisconsin, 54154

Recruiting
Site Public Contact · Contact
920-433-8889WI_research_admin@hshs.org
Matthew L. Ryan · Principal Investigator

Saint Vincent Hospital Cancer Center at Sheboygan

Sheboygan, Wisconsin, 53081

Recruiting
Site Public Contact · Contact
920-433-8889wi_research_admin@hshs.org
Matthew L. Ryan · Principal Investigator

Sheboygan Physicians Group

Sheboygan, Wisconsin, 53081

Recruiting
Site Public Contact · Contact
920-433-8889wi_research_admin@hshs.org
Matthew L. Ryan · Principal Investigator

Essentia Health-Spooner Clinic

Spooner, Wisconsin, 54801

Recruiting
Site Public Contact · Contact
218-786-3308CancerTrials@EssentiaHealth.org
Bret E. Friday · Principal Investigator

Saint Vincent Hospital Cancer Center at Sturgeon Bay

Sturgeon Bay, Wisconsin, 54235-1495

Recruiting
Site Public Contact · Contact
920-433-8889wi_research_admin@hshs.org
Matthew L. Ryan · Principal Investigator

Essentia Health Saint Mary's Hospital - Superior

Superior, Wisconsin, 54880

Recruiting
Site Public Contact · Contact
701-364-6272
Bret E. Friday · Principal Investigator